Nurix Posts $443.5M Cash, Roche Deal Closing Nears with $700M Upfront
NRIX has more than doubled off its 52-week low of $8.195.
Summary
Nurix reported Q2 2026 financials with $9.0M revenue, $89.5M net loss, and $443.5M cash as of May 31, with pro-forma cash of ~$1.14B including the expected $700M Roche upfront. The Roche collaboration, announced in June, is advancing toward close—subject to HSR clearance—with the upfront payment expected within 30 days of effectiveness, as part of a deal valued at up to $2.3 billion. Updated Phase 1b data showed strong ORR of 92.9% in BTKi-experienced, BCL2i-naïve patients and 84.2% in BTKi-naïve patients, reinforcing bexobrutideg's profile. Enrollment continues in the pivotal Phase 2 DAYBreak CLL-201 trial, with preparations underway for the Phase 3 DAYBreak CLL-306 study. The cash position and upcoming Roche payment significantly extend the runway as the pipeline advances.
At the time of this announcement, NRIX was trading at $24.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $8.20 to $25.09. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.